iBio Inc.
| AMEX: IBIO | Healthcare / Biotechnology / USA |
| 1.46 | -0.0400 | -2.67% | Vol 2.46M | 1Y Perf 55.33% |
| Apr 9th, 2021 16:00 DELAYED |
| BID | 1.44 | ASK | 1.46 | ||
| Open | 1.49 | Previous Close | 1.50 | ||
| Pre-Market | - | After-Market | 1.46 | ||
| - - | - -% |
| Target Price | 2.78 | Analyst Rating | — 0.00 | |
| Potential % | 90.41 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | ★★★★ 56.72 | |
| Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | ★★★★+ 63.77 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
| Market Cap | 315.37M | Earnings Rating | Buy | |
| Price Range Ratio 52W % | 9.52 | Earnings Date | 21st May 2021 |
Today's Price Range 1.451.51 | 52W Range 0.83007.45 | 5 Year PE Ratio Range -5.60-0.7000 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -10.43% | ||
| 1 Month | -12.05% | ||
| 3 Months | 21.67% | ||
| 6 Months | -28.78% | ||
| 1 Year | 55.33% | ||
| 3 Years | -30.14% | ||
| 5 Years | -73.93% | ||
| 10 Years | -94.77% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -135.46 | |||
ROE last 12 Months | -45.21 | |||
ROA (5Y Avg) | -22.53 | |||
ROA last 12 Months | -26.09 | |||
ROC (5Y Avg) | -30.27 | |||
ROC last 12 Months | -25.26 | |||
Return on invested Capital Q | -6.01 | |||
Return on invested Capital Y | -4.71 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 13.80 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -81.50 | ||||
| 3.10 | ||||
| 152.71 | ||||
| - | ||||
| -16.20 | ||||
| -0.17 | ||||
| 3.32 | ||||
| 0.50 | ||||
| 277.21M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 17.70 | ||||
| 18.20 | ||||
| 0.23 | ||||
| 0.31 | ||||
| -8.70 | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -919.00 | ||||
| -820.00 | ||||
| -2 007.30 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.24M | ||||
| 0.01 | ||||
| 59.54 | ||||
| 23.11 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2021 | - | -0.04 | - |
| Q01 2021 | - | -0.05 | - |
| Q03 2020 | - | -0.06 | - |
| Q02 2020 | - | -0.69 | - |
| Q01 2020 | - | -0.21 | - |
| Q03 2019 | - | -0.22 | - |
| Q01 2019 | - | -0.25 | - |
| Q03 2018 | - | -0.03 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2021 FY | -0.17 | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 21st May 2021 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 2.46M |
| Shares Outstanding | 216.01M |
| Trades Count | 6.78K |
| Dollar Volume | 16.51M |
| Avg. Volume | 13.81M |
| Avg. Weekly Volume | 2.39M |
| Avg. Monthly Volume | 4.21M |
| Avg. Quarterly Volume | 13.99M |
iBio Inc. (AMEX: IBIO) stock closed at 1.46 per share at the end of the most recent trading day (a -2.67% change compared to the prior day closing price) with a volume of 2.49M shares and market capitalization of 315.37M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 51 people. iBio Inc. CEO is Thomas F. Isett.
The one-year performance of iBio Inc. stock is 55.33%, while year-to-date (YTD) performance is 39.05%. IBIO stock has a five-year performance of -73.93%. Its 52-week range is between 0.83 and 7.45, which gives IBIO stock a 52-week price range ratio of 9.52%
iBio Inc. currently has a PE ratio of -81.50, a price-to-book (PB) ratio of 3.10, a price-to-sale (PS) ratio of 152.71, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -26.09%, a ROC of -25.26% and a ROE of -45.21%. The company’s profit margin is -%, its EBITDA margin is -820.00%, and its revenue ttm is $2.24 Million , which makes it $0.01 revenue per share.
Of the last four earnings reports from iBio Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. iBio Inc.’s next earnings report date is 21st May 2021.
The consensus rating of Wall Street analysts for iBio Inc. is — (0), with a target price of $2.78, which is +90.41% compared to the current price. The earnings rating for iBio Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
iBio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
iBio Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 26.99, ATR14 : 0.21, CCI20 : -89.37, Chaikin Money Flow : 0.02, MACD : -0.10, Money Flow Index : 31.03, ROC : -20.98, RSI : 43.52, STOCH (14,3) : 38.95, STOCH RSI : 0.84, UO : 46.18, Williams %R : -61.05), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of iBio Inc. in the last 12-months were: James P. Mullaney (Option Excercise at a value of $10 463), James P. Mullaney (Sold 11 250 shares of value $18 113 ), Robert L. Erwin (Option Excercise at a value of $115 685), Robert L. Erwin (Sold 124 392 shares of value $204 059 )
iBio Inc.
iBio Inc is a part of the healthcare sector. Its main business is commercialized technologies and product candidates and manufacturing services to clients and collaborators. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates. Its products are used to combat various areas such as fibrotic diseases, cancers, and infectious diseases. The company operates in two segments: biologics development and licensing activities, conducted within iBio, Inc.
CEO: Thomas F. Isett
Telephone: +1 302 355-0650
Address: 8800 HSC Parkway, Bryan 77807-1107, TX, US
Number of employees: 51
